MedTrace Logo

Biomarkers in Acute Heart Failure

NCT00537628 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1641

Last updated 2008-08-01

No results posted yet for this study

Summary

Primary Objectives

1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath.
2. Mid Region pro A-Type Natriuretic Peptide (MR-proANP) is non-inferior to BNP for the diagnosis of HF in patients presenting to the ED with shortness of breath.

Conditions

Sponsors & Collaborators

  • Brahms AG

    lead INDUSTRY

Principal Investigators

  • Alan S Maisel, MD · Veterans Affairs Medical Center, San Diego and University of California, San Diego

  • Stefan D Anker, MD, PhD · Universitätsklinikum Charité, Charité - Campus Virchow

  • Frank Peacock, MD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • United States
  • Germany
  • Greece
  • Italy
  • New Zealand
  • Poland
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00537628 on ClinicalTrials.gov